Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Psychopharmacotherapy of Premenstrual Dysphoric Disorder-New Vistas.

Literature DB >> 35815174

Psychopharmacotherapy of Premenstrual Dysphoric Disorder-New Vistas.

Ahmed Naguy¹, Adel El-Sheshai¹, Sri Haricharan Thiguti¹, Bibi Alamiri¹.

Abstract

Nearly forty percent of women with PMDD remain impaired and resistant to first-line agents. This reflects complexity and heterogeneity of etiopathogenesis at the core of PMDD. Some agents, in the pipeline, sound promising that might usher in a new sparkle in the psychopharmacology of PMDD.

Entities: Chemical

Keywords: PMDD; allopregnanolone; psychopharmacology

Mesh：

Year: 2022 PMID： 35815174 PMCID： PMC9235312

Source DB: PubMed Journal: Psychopharmacol Bull ISSN： 0048-5764

Keyword Cloud
References

6 in total

1. 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder.

Authors: Pedro E Martinez; David R Rubinow; Lynnette K Nieman; Deloris E Koziol; A Leslie Morrow; Crystal E Schiller; Dahima Cintron; Karla D Thompson; Khursheed K Khine; Peter J Schmidt
Journal: Neuropsychopharmacology Date: 2013-08-14 Impact factor: 7.853

2. Brexanolone and postpartum depression: what does it have to do with GABA?

Authors: Ahmed Naguy
Journal: Arch Womens Ment Health Date: 2019-07-13 Impact factor: 3.633

3. Treatment of premenstrual dysphoric disorder with the GABA_A receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial.

Authors: Marie Bixo; Karin Ekberg; Inger Sundström Poromaa; Angelica Lindén Hirschberg; Aino Fianu Jonasson; Lotta Andréen; Erika Timby; Marianne Wulff; Agneta Ehrenborg; Torbjörn Bäckström
Journal: Psychoneuroendocrinology Date: 2017-03-01 Impact factor: 4.905

Psychopharmacotherapy of Premenstrual Dysphoric Disorder-New Vistas.

1. 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder.

2. Brexanolone and postpartum depression: what does it have to do with GABA?

3. Treatment of premenstrual dysphoric disorder with the GABA_A receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial.

4. Premenstrual dysphoric disorder and suicide attempts as a correlation among women in reproductive age.

5. Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial.

6. A diagnostic and statistical manual of mental disorders history of premenstrual dysphoric disorder.

Psychopharmacotherapy of Premenstrual Dysphoric Disorder-New Vistas.

1. 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder.

2. Brexanolone and postpartum depression: what does it have to do with GABA?

3. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial.

4. Premenstrual dysphoric disorder and suicide attempts as a correlation among women in reproductive age.

5. Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial.

6. A diagnostic and statistical manual of mental disorders history of premenstrual dysphoric disorder.

3. Treatment of premenstrual dysphoric disorder with the GABA_A receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial.